The World Health Organisation Prequalification team have announced the prequalification of a fourth misoprostol 200μg product. These tablets are manufactured by China Resources Zizhu Pharmaceutical Co. Ltd., based in Beijing, China. Concept Foundation has been working closely with CR Zizhu, providing technical assistance to achieve WHO prequalification for both this misoprostol product and their mifepristone product, which was prequalified in August this year. This work was done under the auspices of the United Nations Commission on Life Saving Commodities (UNCoLSC), with general support from the David and Lucile Packard Foundation.
This prequalification expands the choice of uterotonics available for international procurement. These are life-saving products that are crucial to reducing maternal mortality caused by post-partum haemorrhage (PPH), which causes more maternal deaths than any other individual cause. More information on these products can be found on our Resources page.